You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MDS classified as IPSS low/int-1

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Anemia in MDS Trial in Plantation, Bronx, Austin (TP-0184)

Completed
  • Anemia in Myelodysplastic Syndromes
  • Plantation, Florida
  • +2 more
Apr 4, 2022

MDS Trial in France, Germany (N-Plate / romiplostim)

Completed
  • Myelodysplastic Syndromes
  • N-Plate / romiplostim
  • Annecy, France
  • +35 more
Sep 7, 2021

Myelodysplastic Syndrome Trial in Worldwide (Lenalidomide)

Completed
  • Myelodysplastic Syndrome
  • Centre City, New Jersey
  • +148 more
Aug 18, 2022

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) Trial in Worldwide (FG-4592, Placebo)

Active, not recruiting
  • Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
  • Los Angeles, California
  • +71 more
Sep 16, 2022

MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Epoetin Alfa
  • Concord, California
  • +100 more
Jul 20, 2023

Myelodysplastic Syndrome, MDS Trial in Gainesville, Tampa (Prednisone, Lenalidomide)

Completed
Has Results
  • Myelodysplastic Syndrome
  • MDS
  • Gainesville, Florida
  • +1 more
Dec 10, 2019

Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Houston (Anti-Thymocyte Globulin,

Recruiting
  • Aplastic Anemia
  • +3 more
  • Anti-Thymocyte Globulin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 1, 2021

MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Oral Azacitidine
  • Placebo for Oral Azacitidine
  • Buenos Aires, Argentina
  • +1 more
Aug 1, 2022

MDS Trial in China, Japan (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
  • +33 more
Aug 16, 2022

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

Myelodysplastic Syndrome, MDS, Refractory Anemia With Excess Blasts Trial in Worldwide (rigosertib, Any approved or

Terminated
  • Myelodysplastic Syndrome
  • +3 more
  • La Jolla, California
  • +157 more
Sep 22, 2022

MDS, Myeloproliferative Chronic Myelomonocytic Leukemia Trial in Houston (Cladribine, Cytarabine, Venetoclax)

Recruiting
  • Myelodysplastic Syndromes
  • Myeloproliferative Chronic Myelomonocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Oct 31, 2022

MDS, Iron Overload Trial in Stanford, Detroit, Houston (Deferasirox)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Iron Overload
  • Stanford, California
  • +2 more
Jun 1, 2021

MDS, Thrombocytopenia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Thrombocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 8, 2022

Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute Trial in Worldwide (Azacitidine,

Active, not recruiting
Has Results
  • Myelodysplastic Syndrome
  • +2 more
  • Daphne, Alabama
  • +241 more
Dec 23, 2022

MDS Trial in Beijing (Lenalidomide, Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking union medical college hospital
Aug 16, 2023

MDS Trial in Beijing (Roxadustat, Luspatercept)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
    Peking union medical college hospital
Aug 17, 2023

Anemia, MDS, Chronic Myelomonocytic Leukemia Trial in France, United States (Sotatercept)

Completed
Has Results
  • Anemia
  • +5 more
  • Denver, Colorado
  • +19 more
Oct 20, 2022

MDS Trial run by the National Cancer Institute (NCI) (decitabine and cedazuridine, BMS-986253)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

MDS Trial (Imetelstat)

Available
  • Myelodysplastic Syndromes
  • (no location specified)
Jun 30, 2023

MDS, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic Trial in Newcastle (Subcutaneous azacitidine, Oral

Not yet recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Subcutaneous azacitidine
  • Oral decitabine/cedazuridine
  • Newcastle, New South Wales, Australia
    Calvary Mater Newcastle
May 29, 2023

MDS, Del(5Q), Anemia Trial in Italy (Luspatercept Injection [Reblozyl])

Recruiting
  • Myelodysplastic Syndromes
  • +3 more
  • Luspatercept Injection [Reblozyl]
  • Alessandria, Italy
  • +22 more
Jun 20, 2023

MDS Trial in Worldwide (Deferasirox, Placebo)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Anaheim, California
  • +71 more
Oct 30, 2020

MDS Trial in Worldwide (Luspatercept, Placebo)

Completed
Has Results
  • Myelodysplastic Syndromes
  • Stanford, California
  • +73 more
Nov 19, 2021